Cargando…

Cellular changes in boric acid-treated DU-145 prostate cancer cells

Epidemiological, animal, and cell culture studies have identified boron as a chemopreventative agent in prostate cancer. The present objective was to identify boron-induced changes in the DU-145 human prostate cancer cell line. We show that prolonged exposure to pharmacologically-relevant levels of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barranco, W T, Eckhert, C D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2006
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3216419/ https://www.ncbi.nlm.nih.gov/pubmed/16495920 http://dx.doi.org/10.1038/sj.bjc.6603009

Ejemplares similares

Boric acid induces cytoplasmic stress granule formation, eIF2α phosphorylation, and ATF4 in prostate DU-145 cells
por: Henderson, Kimberly A., et al.
Publicado: (2014)

The functional significance of microRNA-145 in prostate cancer
por: Zaman, M S, et al.
Publicado: (2010)

Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline
por: Yates, C, et al.
Publicado: (2005)

Activation of the EIF2α/ATF4 and ATF6 Pathways in DU-145 Cells by Boric Acid at the Concentration Reported in Men at the US Mean Boron Intake
por: Kobylewski, Sarah E., et al.
Publicado: (2016)

Receptor Activated Ca(2+) Release Is Inhibited by Boric Acid in Prostate Cancer Cells
por: Henderson, Kimberly, et al.
Publicado: (2009)

The loss of the tumour-suppressor miR-145 results in the shorter disease-free survival of prostate cancer patients
por: Avgeris, M, et al.
Publicado: (2013)

MicroRNA-145 inhibits tumour growth and metastasis in colorectal cancer by targeting fascin-1
por: Feng, Y, et al.
Publicado: (2014)

The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer
por: Villadsen, S B, et al.
Publicado: (2012)

Changes in circulating microRNA levels associated with prostate cancer
por: Bryant, R J, et al.
Publicado: (2012)

Arachidonic acid induction of Rho-mediated transendothelial migration in prostate cancer
por: Brown, M, et al.
Publicado: (2014)

Identification of a hypoxia-regulated miRNA signature in bladder cancer and a role for miR-145 in hypoxia-dependent apoptosis
por: Blick, C, et al.
Publicado: (2015)

miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer
por: Chiyomaru, T, et al.
Publicado: (2010)

Ligand-independent activation of EphA2 by arachidonic acid induces metastasis-like behaviour in prostate cancer cells
por: Tawadros, T, et al.
Publicado: (2012)

Absence of p300 induces cellular phenotypic changes characteristic of epithelial to mesenchyme transition
por: Krubasik, D, et al.
Publicado: (2006)

Influence of omega-6 PUFA arachidonic acid and bone marrow adipocytes on metastatic spread from prostate cancer
por: Brown, M D, et al.
Publicado: (2010)

FTIR-based spectroscopic analysis in the identification of clinically aggressive prostate cancer
por: Baker, M J, et al.
Publicado: (2008)

Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues
por: Riddick, A C P, et al.
Publicado: (2005)

DKC1 overexpression associated with prostate cancer progression
por: Sieron, P, et al.
Publicado: (2009)

Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial
por: Huang, Jiaqi, et al.
Publicado: (2016)

TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer
por: Knight, J F, et al.
Publicado: (2008)

Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia
por: Giskeødegård, Guro F, et al.
Publicado: (2015)

Tissue level, activation and cellular localisation of TGF-β1 and association with survival in gastric cancer patients
por: Hawinkels, L J A C, et al.
Publicado: (2007)

Diagnosis of prostate cancer by detection of minichromosome maintenance 5 protein in urine sediments
por: Dudderidge, T J, et al.
Publicado: (2010)

Cellular differentiation determines the expression of the hypoxia-inducible protein NDRG1 in pancreatic cancer
por: Angst, E, et al.
Publicado: (2006)

Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress
por: Whitaker, H C, et al.
Publicado: (2013)

Study of matrix metalloproteinases and their inhibitors in prostate cancer
por: Escaff, S, et al.
Publicado: (2010)

Prognostic significance of aberrantly silenced ANPEP expression in prostate cancer
por: Sørensen, K D, et al.
Publicado: (2013)

Investigating prostate cancer tumour–stroma interactions: clinical and biological insights from an evolutionary game
por: Basanta, D, et al.
Publicado: (2012)

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer
por: Wilson, C, et al.
Publicado: (2008)

ERK5 signalling in prostate cancer promotes an invasive phenotype
por: Ramsay, A K, et al.
Publicado: (2011)

Involvement of Cyr61 in growth, migration, and metastasis of prostate cancer cells
por: Sun, Z-J, et al.
Publicado: (2008)

Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer
por: Mukherjee, R, et al.
Publicado: (2011)

Identification of markers of prostate cancer progression using candidate gene expression
por: Larkin, S E T, et al.
Publicado: (2012)

Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells
por: McPherson, R A C, et al.
Publicado: (2009)

The differential effects of statins on the metastatic behaviour of prostate cancer
por: Brown, M, et al.
Publicado: (2012)

Different cellular p16(INK4a) localisation may signal different survival outcomes in head and neck cancer
por: Zhao, N, et al.
Publicado: (2012)

Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer
por: Dudderidge, T J, et al.
Publicado: (2007)

Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer
por: Cuzick, J, et al.
Publicado: (2013)

Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer
por: Attard, G, et al.
Publicado: (2008)

P2Y2 receptor promotes cell invasion and metastasis in prostate cancer cells
por: Li, W-H, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5iltbg203frajmea1v10v2c1m1